Literature DB >> 16213631

Interleukin-12 induces a Th1-like response to Burkholderia mallei and limited protection in BALB/c mice.

Kei Amemiya1, Jennifer L Meyers, Sylvia R Trevino, Tran C Chanh, Sarah L Norris, David M Waag.   

Abstract

We evaluated the effect of interleukin (IL)-12 on the immune response to Burkholderia mallei in BALB/c mice. Mice were vaccinated with non-viable B. mallei cells with or without IL-12. There was a seven- to nine-fold increase in IgG2a levels, and a significant increase in the proliferative response and interferon (IFN)-gamma production by splenocytes from mice that received B. mallei and IL-12. We saw an increase in survivors in the groups of mice that received B. mallei and IL-12 when challenged, compared to mice that received only B. mallei or IL-12. The results suggest that IL-12 can enhance the Th1-like immune response to B. mallei and mediate limited protection from a lethal challenge.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213631     DOI: 10.1016/j.vaccine.2005.09.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.

Authors:  Christopher L Hatcher; Tiffany M Mott; Laura A Muruato; Elena Sbrana; Alfredo G Torres
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

2.  Pathological findings and diagnostic implications of a rhesus macaque (Macacca mulatta) model of aerosol exposure to Burkholderia mallei (glanders).

Authors:  Samuel L Yingst; Paul Facemire; Lara Chuvala; David Norwood; Mark Wolcott; Louis Huzella
Journal:  J Med Microbiol       Date:  2015-04-07       Impact factor: 2.472

3.  Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.

Authors:  Shawn D Baron; Rajendra Singh; Dennis W Metzger
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

4.  Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.

Authors:  Andrew Goodyear; Lisa Kellihan; Helle Bielefeldt-Ohmann; Ryan Troyer; Katie Propst; Steven Dow
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

Review 5.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Sara K Bondi; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

6.  Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei.

Authors:  Caroline A Rowland; Ganjana Lertmemongkolchai; Alison Bancroft; Ashraful Haque; M Stephen Lever; Kate F Griffin; Matthew C Jackson; Michelle Nelson; Anne O'Garra; Richard Grencis; Gregory J Bancroft; Roman A Lukaszewski
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

7.  Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders.

Authors:  Mary N Burtnick; Christian Heiss; Rosemary A Roberts; Herbert P Schweizer; Parastoo Azadi; Paul J Brett
Journal:  Front Cell Infect Microbiol       Date:  2012-08-15       Impact factor: 5.293

Review 8.  Burkholderia vaccines: are we moving forward?

Authors:  Leang-Chung Choh; Guang-Han Ong; Kumutha M Vellasamy; Kaveena Kalaiselvam; Wen-Tyng Kang; Anis R Al-Maleki; Vanitha Mariappan; Jamuna Vadivelu
Journal:  Front Cell Infect Microbiol       Date:  2013-02-05       Impact factor: 5.293

9.  Development of novel O-polysaccharide based glycoconjugates for immunization against glanders.

Authors:  Mary N Burtnick; Christian Heiss; A Michele Schuler; Parastoo Azadi; Paul J Brett
Journal:  Front Cell Infect Microbiol       Date:  2012-11-27       Impact factor: 5.293

10.  Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei.

Authors:  Gregory C Whitlock; Roman A Lukaszewski; Barbara M Judy; Slobodan Paessler; Alfredo G Torres; D Mark Estes
Journal:  BMC Immunol       Date:  2008-09-29       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.